Search
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational[A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high
Bezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTechnetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnTechnetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. … It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082]
Synonyms: Technetium Tc 99m nofetumomab merpentan, Technetium Tc-99m nofetumomab merpentanFrovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. … Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalIt has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.
Zimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving … Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeApazunersen
go.drugbank.com/drugs/DB16981InvestigationalApazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]
Categories: Antisense Oligonucleotide Specific to the Antisense Transcript of UBE3AAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal
Naltrexone
go.drugbank.com/drugs/DB00704ApprovedInvestigationalVet approvedThe FDA has approved naltrexone for the treatment of alcohol dependence. … Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome